Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 23,710
Change Today -340.00 / -1.41%
Volume 228.0K
TEVA On Other Exchanges
Symbol
Exchange
New York
OTC US
Mexico
Tel Aviv
Frankfurt
As of 9:33 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by TEVA PHARMACEUTICAL IND LTD (TEVA) in the last 6 months

Announced 05/17/15
Teva Pharmaceutical Industries Limited
Merger/Acquisition

Soros Fund Management LLC sold all of its 0.6% stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the first quarter of 2015. Soros Fund Management sold all the 4.9 million shares of Teva held by it.


TEVA's price was unchanged after the transaction was announced on 05/17/15.
 
Announced 05/13/15
5.00M for Teva Pharmaceutical Industries Limited, New Drug Application for Testosterone Gel
Merger/Acquisition

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) acquired New Drug Application for Testosterone Gel from Teva Pharmaceutical Industries Limited (NYSE:TEVA) for $5 million on May 13, 2015. Upon commercialization, ANI will pay Teva up to $5 million at a rate of 5% of the consideration received by ANI as a result of commercial sale of the product.


TEVA's price was unchanged after the transaction was announced on 05/13/15.
Investor / Buyer
ANI Pharmaceuticals, Inc.
Creditor / Lender
Teva Pharmaceutical Industries Limited
 
Announced 04/21/15
39.64B for Mylan N.V.
Merger/Acquisition

Teva Pharmaceutical Industries Limited (NYSE:TEVA) made a proposal to acquire Mylan N.V. (NasdaqGS:MYL) for $31 billion on April 21, 2015. Teva offered $82 a share in cash and stock for Mylan. The consideration would comprise of approximately 50% cash and 50% stock. The proposal was unanimously approved by the Board of Directors of Teva. This proposal is subject to customary conditions. The transaction would not be subject to a financing condition or require a Teva stockholder ...
Read More


TEVA's price was unchanged after the transaction was announced on 04/21/15.
Investor / Buyer
Teva Pharmaceutical Industries Limited
Creditor / Lender
Abbott Investments Luxembourg S.à.r.l.
BlackRock, Inc.
Paulson & Co. Inc.
Financial Advisor
The Goldman Sachs Group, Inc.
Legal Advisor
Cravath, Swaine & Moore LLP
 
Announced 03/30/15
3.41B for Auspex Pharmaceuticals, Inc.
Merger/Acquisition

Teva Pharmaceutical Industries Limited (NYSE:TEVA) entered into a definitive agreement to acquire Auspex Pharmaceuticals, Inc. (NasdaqGM:ASPX) from a group of shareholders for $3.2 billion in cash on March 29, 2015. The group of shareholders includes Thomas, McNerney & Partners, Panorama Capital, CMEA Capital, Foresite Capital Management, L.L.C. and other shareholders. Under the terms of the deal, Teva will commence a tender offer for all of the outstanding shares of ...
Read More


TEVA's price was unchanged after the transaction was announced on 03/30/15.
Investor / Buyer
Teva Pharmaceutical Industries Limited
Creditor / Lender
BioMed Ventures LP
Deerfield Capital, L.P.
Deerfield Management Company, L.P.
Deerfield Private Design Fund II, L.P.
Deerfield Private Design International II, Ltd.
Deerfield Special Situations Fund, LP
Deerfield Special Situations International Master Fund, L.P.
Foresite Capital Management, L.L.C.
Oxford Finance LLC
Panorama Capital
Panorama Capital I, L.P.
Presidio Partners
Presidio Partners 2007
Thomas, McNerney & Partners
Thomas, McNerney & Partners II, L.P.
Financial Advisor
J.P. Morgan Securities LLC
Legal Advisor
Cooley LLP
 
Announced 03/2/15
Teva Pharmaceutical Industries Ltd., Sellersville, Pennsylvania Facility
Merger/Acquisition

G & W Laboratories, Inc. signed an agreement to acquire Sellersville, Pennsylvania facility from Teva Pharmaceutical Industries Limited (NYSE:TEVA) on March 2, 2015. The transaction includes the grant to G & W of exclusive rights to sell up to two additional Teva products in the U.S. under G & W's label, which Teva will continue to manufacture at its Zagreb, Croatia facility. G & W Laboratories will offer employment to all the employees located in acquire Sellersville. ...
Read More


TEVA's price was unchanged after the transaction was announced on 03/2/15.
Investor / Buyer
G & W Laboratories, Inc.
Creditor / Lender
Teva Pharmaceutical Industries Limited
 
Announced 01/14/15
26.00M for Teva Pharmaceutical Industries Limited, 78,130-Square-Foot Building On 11.9 Acres Of Land
Merger/Acquisition

8800 Doral LLC acquired 78,130-square-foot building on 11.9 acres of land from Teva Pharmaceutical Industries Limited (NYSE:TEVA) for $26 million on January 14, 2015.


TEVA's price was unchanged after the transaction was announced on 01/14/15.
Investor / Buyer
8800 Doral LLC
Creditor / Lender
Teva Pharmaceutical Industries Limited
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:IT 23,710.00 -340.00

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.03 USD -0.31
AbbVie Inc $65.48 USD -0.17
Baxter International Inc $67.37 USD -0.17
Eli Lilly & Co $74.30 USD +0.03
Medtronic PLC $77.82 USD -0.59
View Industry Companies
 

Industry Analysis

TEVA

Industry Average

Valuation TEVA Industry Range
Price/Earnings 19.0x
Price/Sales 2.6x
Price/Book 2.3x
Price/Cash Flow 21.2x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL IND LTD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.